EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access

Representation of Patients With Chronic Kidney Disease in Clinical Trials of Cardiovascular Disease Medications

Julia M T Colombijn, Demy L Idema, Sanne van Beem, Anna Marthe Blokland, Kim van der Braak, M Louis Handoko, Linde F Huis In 't Veld, Tabea Kaul, Nurda Kolagasigil-Akdemir, Mike P T Kusters, Sabine C A Meijvis, Ilse J Oosting und 5 weitere

JAMA Network Open · 07.03.2024 · 7 (3) · e240427

DOI: 10.1001/jamanetworkopen.2024.0427 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift JAMA Network Open, online erschienen am 07.03.2024. Verfasst von Julia M T Colombijn und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, the Netherlands. Hauptthemen laut MEDLINE: Cardiovascular Agents, Cardiovascular Diseases, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Patients with chronic kidney disease (CKD) are at high risk for cardiovascular disease, but their systematic underrepresentation in cardiovascular randomized clinical trials (RCTs) limits the generation of appropriate evidence to guide cardiovascular risk management (CVRM).

Objective

To evaluate the underrepresentation of patients with CKD in cardiovascular RCTs, and to highlight evidence gaps in CVRM medications in this population. Evidence Review A systematic search was conducted in ClinicalTrials.gov from February 2000 through October 2021 for RCTs with full-text publications. If no full-text publications were found in ClinicalTrials.gov, MEDLINE, Embase, and Google Scholar were also searched. Eligible RCTs were those evaluating the effectiveness of antiplatelets, anticoagulants, blood pressure–lowering drugs, glucose-lowering drugs, or cholesterol-lowering drugs in adults with cardiovascular disease or cardiovascular risk factors. Trials with a sample size of fewer than 100 patients were excluded.

Findings

In total, 1194 RCTs involving 2 207 677 participants (mean [SD] age, 63 [6] years; 1 343 970 males [64%]) were included. Since 2000, the percentage of cardiovascular RCTs excluding patients with CKD has increased from 66% to 79% (74% overall [884 RCTs]). In 864 RCTs (72%), more patients were excluded than anticipated on safety grounds (63% [306] of trials required no dose adjustment, and 79% [561] required dose adjustment). In total, 158 RCTs (13%) reported results for patients with CKD separately (eg, in subgroup analyses). Significant evidence gaps exist in most CVRM interventions for patients with CKD, particularly for those with CKD stages 4 to 5. Twenty-three RCTs (2%) reported results for patients with an estimated glomerular filtration rate less than 30 mL/min/1.73 m 2 , 15 RCTs (1%) reported for patients receiving dialysis, and 1 RCT (0.1%) reported for recipients of kidney transplant. Conclusions and Relevance Results of this systematic review suggest that representation of patients with CKD in cardiovascular RCTs has not improved in the past 2 decades and that these RCTs excluded more patients with CKD than expected on safety grounds. Lack of reporting or underreporting of results for this patient population is associated with evidence gaps in the effectiveness of most CVRM medications in patients with all stages of CKD, particularly CKD stages 4 to 5.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular AgentsCardiovascular DiseasesRenal Insufficiency, ChronicHumansAntihypertensive AgentsRenal DialysisRandomized Controlled Trials as Topic

Substanzen

Antihypertensive AgentsCardiovascular Agents

Autor:innen und Institutionen

  • Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Cochrane Netherlands, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.
  • Amsterdam Cardiovascular Sciences (Heart Failure and Arrhythmias), Amsterdam, the Netherlands.
  • Medical Library, Amsterdam UMC, University of Amsterdam, Amsterdam Public Health, Amsterdam, the Netherlands.

Zitieren

APA

Colombijn, J. M. T., Idema, D. L., van Beem, S., Blokland, A. M., van der Braak, K., Handoko, M. L., In 't Veld, L. F. H., Kaul, T., Kolagasigil-Akdemir, N., Kusters, M. P. T., Meijvis, S. C. A., Oosting, I. J., Spijker, R., Bots, M. L., Hooft, L., Verhaar, M. C., & Vernooij, R. W. M. (2024). Representation of Patients With Chronic Kidney Disease in Clinical Trials of Cardiovascular Disease Medications. JAMA Network Open, 7(3), e240427. https://doi.org/10.1001/jamanetworkopen.2024.0427

Vancouver

Colombijn JMT, Idema DL, van Beem S, Blokland AM, van der Braak K, Handoko ML, et al. Representation of Patients With Chronic Kidney Disease in Clinical Trials of Cardiovascular Disease Medications. JAMA Network Open. 2024;7(3):e240427. doi:10.1001/jamanetworkopen.2024.0427

BibTeX
@article{Colombijn2024,
  author = {Colombijn, Julia M T and Idema, Demy L and van Beem, Sanne and Blokland, Anna Marthe and van der Braak, Kim and Handoko, M Louis and In 't Veld, Linde F Huis and Kaul, Tabea and Kolagasigil-Akdemir, Nurda and Kusters, Mike P T and Meijvis, Sabine C A and Oosting, Ilse J and Spijker, Rene and Bots, Michiel L and Hooft, Lotty and Verhaar, Marianne C and Vernooij, Robin W M},
  title = {Representation of Patients With Chronic Kidney Disease in Clinical Trials of Cardiovascular Disease Medications},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {3},
  pages = {e240427},
  doi = {10.1001/jamanetworkopen.2024.0427}
}
Kostenlos starten →